About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
IOVA - Iovance Biotherapeut...| Previous Close | $22.80 | Open | $22.80 |
| Volume | 2.15M | Market Cap | 3.485B |
| Yield | Last Dividend |
| Iovance Biotherapeutics to Host Second Q... | 07/19/21 |
| SAN CARLOS, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing nove... | |
| NASDSQ:IOVA Shareholder Alert: Investiga... | 07/01/21 |
| An investigation on behalf of investors in Iovance Biotherapeutics, Inc. (NASDSQ:IOVA) shares over potential wrongdoing at Iovance Biotherapeutics, In... | |
| Iovance Biotherapeutics to Host Conferen... | 06/29/21 |
| SAN CARLOS, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing nove... | |
| Iovance Biotherapeutics Announces Clinic... | 06/29/21 |
| 21.4% Overall Response Rate (ORR) in Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC) Patients Following One or More Prior Systemic ... | |
| Is Iovance Biotherapeutics, Inc. (IOVA) ... | 06/28/21 |
| No summary available. | |
| Iovance Bio reports 33-month follow up d... | 06/06/21 |
| No summary available. | |
| Iovance Biotherapeutics posts positive d... | 06/04/21 |
| No summary available. | |
| NASDSQ: IOVA Shareholder Notice: Investi... | 06/02/21 |
| An investigation for investors in Iovance Biotherapeutics, Inc. (NASDSQ: IOVA) shares over potential securities laws violations by Iovance Biotherapeu... | |
| Iovance: Down And Rebound | 05/30/21 |
| No summary available. | |
| Stock Alert: Iovance Biotherapeutics Up ... | 05/20/21 |
| Iovance Biotherapeutics, Inc. (IOVA) shares are trading higher on Thursday morning. The shares have been gaining since Wednesday as the company announ... | |
| Ademi LLP Investigates Claims of Securit... | 05/20/21 |
| MILWAUKEE, May 20, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Iovance (NASDAQ: IOVA). The investigation ... | |
| Iovance Bio''s lifileucel combo regime s... | 05/20/21 |
| No summary available. | |
| The Law Offices of Frank R. Cruz Announc... | 05/19/21 |
| LOS ANGELES--(BUSINESS WIRE)---- $IOVA #investors--The Law Offices of Frank R. Cruz Announces Investigation of Iovance Biotherapeutics, Inc. (IOVA) on... | |
| HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS,... | 05/19/21 |
| SAN FRANCISCO, May 19, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ) investors with significant losses to... | |
| HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS,... | 05/19/21 |
| SAN FRANCISCO, May 19, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) investors with significant losses to ... | |
| Iovance cut to hold at Stifel as CEO dep... | 05/19/21 |
| No summary available. | |
| IOVA INVESTIGATION ALERT: Bernstein Lieb... | 05/19/21 |
| NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities ... | |
| Iovance Provides Update From US FDA For ... | 05/19/21 |
| Shares of Iovance Biotherapeutics, Inc. (IOVA) plunged around 15% in early trading on Wednesday as the company provided a regulatory update from the ... | |
| Iovance Biotherapeutics Shares Slip 10% ... | 05/18/21 |
| (RTTNews) - Shares of Iovance Biotherapeutics, Inc. (IOVA) slipped over 10% on Tuesday extended session after the late-stage biotechnology company dev... | |
| Iovance shares fall after lifileucel reg... | 05/18/21 |
| No summary available. | |
| Iovance Biotherapeutics Provides Regulat... | 05/17/21 |
| Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced... | |
| Journal of Clinical Oncology Publishes C... | 05/11/21 |
| Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrat... | |
| Iovance Biotherapeutics Inc Shares Close... | 03/05/21 |
| Iovance Biotherapeutics Inc shares closed this week 20.0% lower than it did at the end of last week. The stock is currently down 32.0% year-to-date, ... | |
| Iovance Biotherapeutics Inc Shares Close... | 02/26/21 |
| Iovance Biotherapeutics Inc shares closed this week 21.0% lower than it did at the end of last week. The stock is currently down 19.6% year-to-date, ... | |
| Iovance Biotherapeutics Inc Shares Near ... | 01/14/21 |
| Iovance Biotherapeutics Inc shares closed today at 1.9% below its 52 week high of $52.03, giving the company a market cap of $7B. The stock is curren... | |
| Iovance Biotherapeutics Inc Shares Near ... | 12/24/20 |
| Iovance Biotherapeutics Inc shares closed today at 1.4% below its 52 week high of $50.26, giving the company a market cap of $7B. The stock is curren... | |
| Iovance Biotherapeutics Inc Shares Climb... | 12/14/20 |
| Iovance Biotherapeutics Inc shares closed 0.6% higher than its previous 52 week high, giving the company a market cap of $7B. The stock is currently ... | |
| Iovance Biotherapeutics Inc Shares Close... | 12/11/20 |
| Iovance Biotherapeutics Inc shares closed the week 15.9% higher than it did at the end of last week. The stock is currently up 80.5% year-to-date, up... | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Biotechnology | Robert Gadimian | 26.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
